A professional from pharmaceutical company GSK must choose much to integrate a lately acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's Global mind of R&D, championed the acquisition of Sirtris to get into its potentially revolutionary science. Slaoui must balance the necessity to recoup investor value after having to pay a 2-occasions premium for Sirtris together with his need to retain Christoph Westphal, Sirtris's co-founder and CEO, along with other key people at the organization. His need to safeguard Sirtris from GSK's size and paperwork happens in an occasion when GSK has released major alterations in its R&D organization, which concentrate on decentralizing and externalizing R&D, in addition to revamping the resource allocation way to parallel much more of a investment capital-based model. The case also explores the sights of Christoph Westphal around the early challenges from the integration and also the impact GSK was getting on Sirtris. May be used along with another case that concentrates on Sirtris's business design.
Estimated Submission On |